Literature DB >> 10882296

ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling.

R Pinkas-Kramarski1, I Alroy, Y Yarden.   

Abstract

The ErbB/HER family of transmembrane receptor tyrosine kinases includes four members that bind more than two dozens ligands sharing an epidermal growth factor- (EGF)3 like motif. This family plays a pivotal role in cell lineage determination in a variety of tissues, including mesenchyme-epithelial inductive processes and the interactions between neurons and muscle, glia and Schwann cells. Certain ligands and receptors of the family, especially the ErbB-2 receptor tyrosine kinase, contribute to a relatively virulent phenotype of some human tumors; most notable are carcinomas of secretory epithelia. This large variety of biological signals is generated through a combinatorial network of signal transduction in which different ErbB ligands are apparently capable of stabilizing discrete homo- and heterodimeric receptor complexes, each coupled to a specific set of cytoplasmic signaling proteins. Because each receptor is unique in terms of catalytic activity, cellular routing and transmodulation, the resulting network allows not only an enormous potential for signal diversification but also fine tuning and stringent control of cellular functions. ErbB-2 emerges as a master coordinator of the network, prolonging and amplifying signaling by decelerating the dissociation rates of its heterologous ligands. Thus, the tumorigenic action of ErbB-2 may be attributed to its ability to act as a shared signaling subunit, rather than by functioning as a bone fide receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10882296     DOI: 10.1023/a:1026343528967

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  60 in total

1.  Structural and functional aspects of the multiplicity of Neu differentiation factors.

Authors:  D Wen; S V Suggs; D Karunagaran; N Liu; R L Cupples; Y Luo; A M Janssen; N Ben-Baruch; D B Trollinger; V L Jacobsen
Journal:  Mol Cell Biol       Date:  1994-03       Impact factor: 4.272

2.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

3.  A reciprocal cell-cell interaction mediated by NT-3 and neuregulins controls the early survival and development of sympathetic neuroblasts.

Authors:  J M Verdi; A K Groves; I Fariñas; K Jones; M A Marchionni; L F Reichardt; D J Anderson
Journal:  Neuron       Date:  1996-03       Impact factor: 17.173

4.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts.

Authors:  Y Kokai; J N Myers; T Wada; V I Brown; C M LeVea; J G Davis; K Dobashi; M I Greene
Journal:  Cell       Date:  1989-07-28       Impact factor: 41.582

5.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype.

Authors:  D W Threadgill; A A Dlugosz; L A Hansen; T Tennenbaum; U Lichti; D Yee; C LaMantia; T Mourton; K Herrup; R C Harris
Journal:  Science       Date:  1995-07-14       Impact factor: 47.728

6.  Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases.

Authors:  D Karunagaran; E Tzahar; N Liu; D Wen; Y Yarden
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

7.  Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling.

Authors:  D Graus-Porta; R R Beerli; N E Hynes
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

8.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.

Authors:  H B Muss; A D Thor; D A Berry; T Kute; E T Liu; F Koerner; C T Cirrincione; D R Budman; W C Wood; M Barcos
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

Review 9.  Neu and its ligands: from an oncogene to neural factors.

Authors:  E Peles; Y Yarden
Journal:  Bioessays       Date:  1993-12       Impact factor: 4.345

10.  Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.

Authors:  C Wallasch; F U Weiss; G Niederfellner; B Jallal; W Issing; A Ullrich
Journal:  EMBO J       Date:  1995-09-01       Impact factor: 11.598

View more
  31 in total

Review 1.  EGF-related peptides and their receptors in mammary gland development.

Authors:  R P DiAugustine; R G Richards; J Sebastian
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

Review 2.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

Review 3.  The ErbB receptors as targets for breast cancer therapy.

Authors:  J Albanell; J Baselga
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

4.  Neuregulins rescue PC12-ErbB-4 cells from cell death induced by beta-amyloid peptide: involvement of PI3K and PKC.

Authors:  Ayelet Di Segni; Ezra Shaharabani; Reuven Stein; Ronit Pinkas-Kramarski
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

5.  Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.

Authors:  M Alimandi; L M Wang; D Bottaro; C C Lee; A Kuo; M Frankel; P Fedi; C Tang; M Lippman; J H Pierce
Journal:  EMBO J       Date:  1997-09-15       Impact factor: 11.598

Review 6.  Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality.

Authors:  Adriana Dusso; Maria Vittoria Arcidiacono; Jing Yang; Masanori Tokumoto
Journal:  J Steroid Biochem Mol Biol       Date:  2010-03-30       Impact factor: 4.292

7.  Bivalence of EGF-like ligands drives the ErbB signaling network.

Authors:  E Tzahar; R Pinkas-Kramarski; J D Moyer; L N Klapper; I Alroy; G Levkowitz; M Shelly; S Henis; M Eisenstein; B J Ratzkin; M Sela; G C Andrews; Y Yarden
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

8.  AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression.

Authors:  H M Chen; K L Schmeichel; I S Mian; S Lelièvre; O W Petersen; M J Bissell
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

9.  Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival.

Authors:  L Moro; M Venturino; C Bozzo; L Silengo; F Altruda; L Beguinot; G Tarone; P Defilippi
Journal:  EMBO J       Date:  1998-11-16       Impact factor: 11.598

10.  Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss.

Authors:  José Manuel Fernández-Real; Javier A Menendez; Gema Frühbeck; José María Moreno-Navarrete; Alejandro Vazquez-Martín; Wifredo Ricart
Journal:  Nutr Metab (Lond)       Date:  2010-02-25       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.